Powder: -20°C for 3 years
In solvent: -80°C for 2 years
JH-II-127 is an orally inhibitor of leucine-rich repeat kinase 2 (<a href="/target/LRRK2" style="display: inline; color: #c13a36">LRRK2</a>). It inhibits WT <a href="/target/LRRK2" style="display: inline; color: #c13a36">LRRK2</a>, G2019S <a href="/target/LRRK2" style="display: inline; color: #c13a36">LRRK2</a> and A2016T <a href="/target/LRRK2" style="display: inline; color: #c13a36">LRRK2</a> (IC50s = 6.6, 2.2, and 47.7 nM, respectively),
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 87.00 | |
5 mg | In stock | $ 134.00 | |
10 mg | In stock | $ 205.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 633.00 | |
100 mg | In stock | $ 1,066.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 143.00 |
Description | JH-II-127 is an orally inhibitor of leucine-rich repeat kinase 2 (LRRK2). It inhibits WT LRRK2, G2019S LRRK2 and A2016T LRRK2 (IC50s = 6.6, 2.2, and 47.7 nM, respectively), |
Targets&IC50 | WT LRRK2:6.6 nM , G2019S LRRK2:2.2 nM , A2016T LRRK2:47.7 nM |
In vivo | JH-II-127 (0.1-0.3 μM) inhibits phosphorylation of the serines at positions 910 and 935 of WT LRRK2 and LRRK2G2019S in vitro.?It also inhibits Ser935 phosphorylation in vivo in mouse brain, spleen, and kidney when administered at a dose of 30 mg/kg. |
Molecular Weight | 416.87 |
Formula | C19H21ClN6O3 |
CAS No. | 1700693-08-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 30 mg/mL (71.97 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JH-II-127 1700693-08-8 Autophagy LRRK2 HEK293 JHII127 3T3 cells Inhibitor LRRK2-G2019S Ser935 Leucine-rich repeat kinase 2 parkinson’s disease inhibit JH II 127 LRRK2-A2016T inhibitor